Aprea Therapeutics
APRE
67 hedge funds and large institutions have $44.8M invested in Aprea Therapeutics in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 14 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 15
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
2% more funds holding
Funds holding: 66 → 67 (+1)
0.33% less ownership
Funds ownership: 2.43% → 2.11% (-0.33%)
11% less capital invested
Capital invested by funds: $50.3M → $44.8M (-$5.47M)
22% less call options, than puts
Call options by funds: $201K | Put options by funds: $259K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$3.69M |
| 2 |
Morgan Stanley
New York
|
+$3.06M |
| 3 |
Two Sigma Advisers
New York
|
+$1.82M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$1.77M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.21M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$4.42M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$3.35M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$2.55M |
| 5 |
VVM
Versant Venture Management
San Francisco,
California
|
-$972K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Squarepoint
New York
| – | -$129K | -1,309 | Closed |
|
77
Victory Capital Management
San Antonio,
Texas
| – | -$74K | -752 | Closed |
|
78
Jane Street
New York
| – | -$58K | -593 | Closed |
|
|
CSS
79
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$53K | -540 | Closed |
|
|
PAM
80
Panagora Asset Management
Boston,
Massachusetts
| – | +$233 | +2 | New |
|
APRE Hedge Fund Activity: Q1 2021 in Review
67 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q1 2021, worth a combined $44.8M — down 11% from $50.3M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new APRE positions and 14 closed out — a net gain of 2 holders — while 20 added to existing stakes and 15 trimmed.
The largest buyer was SG Americas Securities, adding an estimated $3.69M. The largest seller was Fidelity Investments, exiting entirely with an estimated $6.21M sold.
- 67 institutional investors held Aprea Therapeutics (APRE) as of Q1 2021, up from 66 in Q4 2020.
- Funds reported $44.8M of Aprea Therapeutics stock for Q1 2021, down 11% quarter-over-quarter.
- 16 funds opened new Aprea Therapeutics positions in Q1 2021 and 14 closed out, a net change of +2 holders.
- The largest Aprea Therapeutics buyer in Q1 2021 was SG Americas Securities, an estimated $3.69M added.
- The largest Aprea Therapeutics seller in Q1 2021 was Fidelity Investments, an estimated $6.21M sold.
Based on aggregated 13F filings for Q1 2021.